Market survey predictions on the future of US Pap testing

CytoJournal

Volumn 6, Issue , 2009, Pages

  Austin, R ^a   Benstein, Barbara ^a   Bentz, Joel ^a   Bigner, Sandra ^a   Freund, Gregory ^a   Rocco, Gregory ^a   Ramzy, Ibrahim ^a   Savaloja, Lynnette ^a   Shidham, Vinod ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

CANCER PREVENTION; DNA DETERMINATION; HEALTH SURVEY; HUMAN; NOTE; PAPANICOLAOU TEST; PRACTICE GUIDELINE; SCREENING TEST; UNITED STATES; UTERINE CERVIX CANCER; WART VIRUS;

EID: 77956596472     PISSN: 09745963     EISSN: 17426413     Source Type: Journal    
DOI: 10.4103/1742-6413.55885     Document Type: Note

References (30)

1. Zur Hausen H. Papillomaviruses in the causation of human cancers: A brief historical account. Virology 2009;384:260-5.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
3. Solomon D, Schiffman M, Tarone R; ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9. (Pubitemid 32219816)
4. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003;348:489-90.
5. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43. (Pubitemid 46740303)
6. Eltoum IA, Roberson J. Impact of expected changes in national papanicolaou test volume on the cytotechnology labor market: An impending crisis. Am J Clin Pathol 2007;128:665-70.
7. Eltoum IA Roberson J. Impact of HPV testing, HPV vaccine development, and changing screening frequency on national pap test volume. Cancer Cytopathol 2007;111:34-40.
8. Solomon D, Breen N, McNeel T. Cervical cancer screening rates in the United States and the potential impact of implementation of screening guidelines. CA Cancer J Clin 2007;57:105-11.
9. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer Cytopathol 2007;11:145-53.
10. Covell J, Stoler MH. Human papillomavirus testing, vaccination, and gynecologic screening. Am J Clin Pathol 2007;128:726-8.
11. Austin RM. Dismantling of the US cytotechnology educational infrastructure is premature and carries significant risks. Arch Pathol Lab Med 2008;132:154-8.
12. Stoler MH. HPV vaccine to transform testing protocl, profession sooner rather than later. Critical Values 2009;2:26-7.
13. Austin RM. Not so fast: Pap to remain screening centerpiece for foreseeable future. Critical Values 2009;2:28-9.
14. American College of Obstetricians and Gynecologists. Routine cancer screening. ACOG Committee Opinion No. 356. Obstet Gynecol 2006;108:1611-3.
15. Sirovich BE, Welch HG. The frequency of Pap smear screening in the United States. J Gen Intern Med 2004;19:243-50.
16. Miller AB. The (in) efficiency of cervical screening in Europe. Eur J Cancer 2002;38:321-6.
17. Canfell K, Sitas F, Beral V. Cervical cancer in Australia and the United Kingdom: Comparison of screening policy and uptake, and cancer incidence and mortality. Med J Aust 2006;185:482-6.
18. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62. (Pubitemid 35446606)
19. US Preventive Services Task Force. Screening for Cervical Cancer. Rockville, MD: Agency for Healthcare Research and Quality; 2003. Available from: http://www.ahrq.gov/clinic/uspstf/uspscerv.htm. [accessed on 2006 Nov 20].
20. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol 2003;102:417-27.
21. Noller KL, Bettes B, Zinberg S, Schulkin J. Cervical cytology screening practices among obstetrician-gynecologists. Obstet Gynecol 2003;102:259-65.
22. Saraiya M, Roland K, Benard V, Richardson L. HPV co-testing in the United States: Minimal impact on screening intervals. J Lower Genital Tract Dis 2008;12:170-1.
23. Cooper CP, Saraiya M, McLean TA, Hannan J, Liesmann JM, Rose SW, et al. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program. J Women's Health 2005;14:670-8.
24. Ubel PA, Jepson C, Baron J, Hershey JC, Asch DA. The influence of cost-effectiveness information on physicians' cancer screening recommendations. Soc Sci Med 2003;56:1727-36.
25. Massad LS, Einstein M, Myers E, Wheeler CM, Weintzensen N, Solomom D. The impact of human papillomavirus vaccination on cervical cancer prevention efforts. Gynecol Oncol 2009;114: 360-4.
26. Cuzik J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-101.
27. Franco EL, Cuzik J. Cervical cancer screening following prophylactic human apillomavirus vaccination. Vaccine 2008;26S:A16-23.
28. Brook RH. The Science of Healthcare Reform. JAMA 2009;301:2486-7.
29. Rittenhouse DR, Shortell SM. The patient-centered medical home: Will it stand the test of health reform? JAMA 2009;301:2038-40.
30. Sirovich BE, Woloshin S, Schwartz LM. Screening for cervical cancer: Will women accept less? Am J Med 2005;118:151-8.